All In Biotech

Drug Trial Radar · NCT07281716

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

A Phase 1b/2 Study of Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Dec 15, 2028

Study completion Dec 15, 2028

Sponsor

Lead sponsor
Dan FengAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Coherus Oncology, Inc.; Cantargia AB
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer. Phase 1b will assess dose-limiting toxicity (DLT), while Phase 2 will evaluate objective response rate (ORR), including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). Exploratory analyses will investigate immunomodulatory effects through tumor and peripheral blood studies, and treatment will continue every 3 weeks for up to 1 year or until disease progression.

Conditions

  • Metastatic Microsatellite Stable Colorectal Carcinoma

Interventions

  • NadunolimabDrug

    5 mg/kg intravenously (IV) every 3 weeks (Q3W)

  • ToripalimabDrug

    240 mg IV every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicities (DLTs)Time frame: The first cycle (day1 - day21) constitutes the DLT window.
  2. Objective Response Rate (ORR)Time frame: Treatment initiation through 12 months, or until documented disease progression or initiation of new anti-cancer therapy, whichever occurs first

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.